[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Registration::
Contact us::
Site Facilities::
Webmail::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
:: Volume 17, Issue 3 (Fall 2007) ::
MEDICAL SCIENCES 2007, 17(3): 139-146 Back to browse issues page
Comparing the efficacy of Avonex, Rebif and Betaferon in motor disability (Expanded Disability Status Scale) and relapsing rate of multiple sclerosis patients
Mehrdokht Mazdeh
, mehrdokhtmazdeh@ yahoo.com
Abstract:   (20111 Views)
Background: Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the central nervous system (CNS) that is a leading cause of disability in young adults. The aim of the present study was to compare the relative efficacies of Avonex, Rebif and Betaferon in EDSS and relapsing rate in MS patients.
Materials and methods: 126 patients with multiple sclerosis were randomly allocated to the three treatment groups. The first group received Avonex (47.6%), the second group received Rebif (28.5%), and the third group received Betaferon (23.8%). For all patients, first and final EDSS and relapsing rate was assessed.
Results: The mean age of patients was 31.1±8.6 years and 80.2% of patients were female. Differences between mean of first and final EDSS were statistically significant in three groups (p<0.05). The mean of EDSS score changes in Avonex, Betaferon and Rebif groups were 1.38 (31.2%), 1.30(24.3%) and 1.45(30.7%) (NS). In Avonex and Betaferon groups, the difference between attack of MS disease before and after treatment was significant (p<0.05), however, the difference in Rebif group was not significant (NS). The mean decrease relapse of MS disease in Avonex, Betaferon and Rebif groups were 0.69(40.1%), 0.60(42.8%) and 1.25(62.5%) (NS).
Conclusion: Treatment with these three drugs has significantly reduced EDSS score, however, relapsing rate was significantly decreased in Rebif group.
Keywords: Multiple sclerosis, Avonex, Betaferon, Rebif, EDSS(Expanded Disability Status Scale).
Full-Text [PDF 178 kb]   (11654 Downloads)    
Subject: Epidemiology
Received: 2006/09/6 | Published: 2007/09/15
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Mazdeh M. Comparing the efficacy of Avonex, Rebif and Betaferon in motor disability (Expanded Disability Status Scale) and relapsing rate of multiple sclerosis patients . MEDICAL SCIENCES 2007; 17 (3) :139-146
URL: http://tmuj.iautmu.ac.ir/article-1-66-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 17, Issue 3 (Fall 2007) Back to browse issues page
فصلنامه علوم پزشکی دانشگاه آزاد اسلامی واحد پزشکی تهران Medical Science Journal of Islamic Azad Univesity - Tehran Medical Branch
Persian site map - English site map - Created in 0.06 seconds with 37 queries by YEKTAWEB 4645